Ezzedine Abderrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ezzedine Abderrahim has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Amel Harzallah
Service de médecine A, hôpital Charles Nicolle, Tunis, Tunisie
2 shared publications Fethi Ben Hamida
Service de médecine A, hôpital Charles Nicolle, Tunis, Tunisie
2 shared publications- S. Turki
Service de Médecine Interne A, Hôpital Charles Nicolle, Tunis, Tunisie
2 shared publications - Soumaya Chargui
Service de Médecine Interne A Hôpital Charles Nicolle/Laboratoire de Recherche de Pathologie Rénale (LR00SP01), Tunis, Tunisie
2 shared publications A. Fradj
Service de Médecine Interne A, Hôpital Charles Nicolle, Tunis, Tunisie
1 shared publicationAfef Dridi
DaVita Health Care Riyadh Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 16 May 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Renal AA amyloidosis associated with inflammatory bowel disease
Renal AA amyloidosis is a rare but severe complication of inflammatory bowel disease (IBD), associated with significant renal morbidity and poor prognosis.
- 16 May 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessRenal AA amyloidosis associated with inflammatory bowel disease
Renal AA amyloidosis is a rare but severe complication of inflammatory bowel disease (IBD), associated with significant renal morbidity and poor prognosis.
- 1 December 2023
- Published by JLE in Nephrologie & Therapeutique
- Vol. 19 (7) , 594-599
Amylose rénale AA révélant un plasmocytome extra-médullaire : étude de cas
Solitary plasmacytoma is a rare, localized malignancy. Bone localizations are the most common. Extramedullary plasmacytomas are much rarer. They are most often in the upper respiratory tract and can be complicated by amyloidosis. Here is an original report of a mediastinal extramedullary plasmacytoma revealed by type AA renal amyloidosis. We present the case of a 52-year-old patient with mediastinal extramedullary plasmocytoma diagnosed by renal failure due to type AA renal amyloidosis. Treatment was based on surgery with chemotherapy based on prednisone and melphalan. The patient presented end-stage renal failure that required hemodialysis at discharge. Extramedullary plasmacytoma is a rare tumour that may be associated with amyloidosis, usually type AL. To our knowledge, its association with AA amyloidosis has not been reported in the literature. Treatment is based on surgery combined with radiotherapy or chemotherapy.
- 1 December 2023
- Published by JLE in Nephrologie & Therapeutique
- Vol. 19 (7) , 594-599
Amylose rénale AA révélant un plasmocytome extra-médullaire : étude de cas
Solitary plasmacytoma is a rare, localized malignancy. Bone localizations are the most common. Extramedullary plasmacytomas are much rarer. They are most often in the upper respiratory tract and can be complicated by amyloidosis. Here is an original report of a mediastinal extramedullary plasmacytoma revealed by type AA renal amyloidosis. We present the case of a 52-year-old patient with mediastinal extramedullary plasmocytoma diagnosed by renal failure due to type AA renal amyloidosis. Treatment was based on surgery with chemotherapy based on prednisone and melphalan. The patient presented end-stage renal failure that required hemodialysis at discharge. Extramedullary plasmacytoma is a rare tumour that may be associated with amyloidosis, usually type AL. To our knowledge, its association with AA amyloidosis has not been reported in the literature. Treatment is based on surgery combined with radiotherapy or chemotherapy.
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 615
Hypercalcémie chez le sujet âgé : à propos de 62 cas
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 615
Hypercalcémie chez le sujet âgé : à propos de 62 cas
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#4043 FABRY DISEASE: A RARE ENTITY IN THE NEPHROLOGY SETTING
Background and Aims: Fabry disease is a rare genetic disorder that affects multiple organs, including the kidneys. It is characterized by the accumulation of globotriaosylceramide (Gb3) in various tissues and organs, leading to progressive interstitial fibrosis and renal dysfunction. We aim to determine the renal manifestations of Fabry disease in particular the histological aspects. Method: This study analyzed 9 patients with Fabry disease and renal involvement in a retrospective, single-center analysis. Clinical and biological data, as well as histologic findings, were collected based on patient's observations. Results: Data was collected from 9 patients, including 7 males and 2 females, with an average age at diagnosis of 25.2 years (ranging from 17 to 32 years). All patients showed depleted activity of alpha 1 glycosidase, confirming the diagnosis. Acrosyndrome and vascular cutaneous lesions (angiokeratomas) were the dominant signs at admission with respectively (n=7; n=4), with only 3 patients being identified through familial screening without symptoms. Uncontrolled Hypertension was noted in 2 patients. Renal manifestations included renal hyperfiltration in 2 cases, isolated proteinuria in 4 patients, and renal failure in 3 others with a mean serum creatinine levels of 240 ± 36 µmol/l. Four patients underwent renal biopsy, which showed characteristic lesions of Fabry disease with sphingolipid accumulation and tubular cell vacuolization. Thickening of the glomerular capillary walls was observed in one patient. Interstitial fibrosis and tubular atrophy were noted in 3 patients. All patients received enzyme replacement therapy. Angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin II receptors blockers (ARB) were uses in 6 patients. Five patients progressed to terminal stage of renal failure requiring dialysis after an average follow-up period of 13±2.7 years. Four patients died from cardiovascular complications. Conclusion: Early recognition and diagnosis of Fabry disease from the onset of glomerular hyperfiltration and albuminuria are crucial for the initiation of appropriate treatment and management, which can help to delay the progression of renal and other organ damage.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#4043 FABRY DISEASE: A RARE ENTITY IN THE NEPHROLOGY SETTING
Background and Aims: Fabry disease is a rare genetic disorder that affects multiple organs, including the kidneys. It is characterized by the accumulation of globotriaosylceramide (Gb3) in various tissues and organs, leading to progressive interstitial fibrosis and renal dysfunction. We aim to determine the renal manifestations of Fabry disease in particular the histological aspects. Method: This study analyzed 9 patients with Fabry disease and renal involvement in a retrospective, single-center analysis. Clinical and biological data, as well as histologic findings, were collected based on patient's observations. Results: Data was collected from 9 patients, including 7 males and 2 females, with an average age at diagnosis of 25.2 years (ranging from 17 to 32 years). All patients showed depleted activity of alpha 1 glycosidase, confirming the diagnosis. Acrosyndrome and vascular cutaneous lesions (angiokeratomas) were the dominant signs at admission with respectively (n=7; n=4), with only 3 patients being identified through familial screening without symptoms. Uncontrolled Hypertension was noted in 2 patients. Renal manifestations included renal hyperfiltration in 2 cases, isolated proteinuria in 4 patients, and renal failure in 3 others with a mean serum creatinine levels of 240 ± 36 µmol/l. Four patients underwent renal biopsy, which showed characteristic lesions of Fabry disease with sphingolipid accumulation and tubular cell vacuolization. Thickening of the glomerular capillary walls was observed in one patient. Interstitial fibrosis and tubular atrophy were noted in 3 patients. All patients received enzyme replacement therapy. Angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin II receptors blockers (ARB) were uses in 6 patients. Five patients progressed to terminal stage of renal failure requiring dialysis after an average follow-up period of 13±2.7 years. Four patients died from cardiovascular complications. Conclusion: Early recognition and diagnosis of Fabry disease from the onset of glomerular hyperfiltration and albuminuria are crucial for the initiation of appropriate treatment and management, which can help to delay the progression of renal and other organ damage.
- 22 December 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (4) , 1087-1100
Toward generalizing the use of artificial intelligence in nephrology and kidney transplantation
With its robust ability to integrate and learn from large sets of clinical data, artificial intelligence (AI) can now play a role in diagnosis, clinical decision making, and personalized medicine. It is probably the natural progression of traditional statistical techniques. Currently, there are many unmet needs in nephrology and, more particularly, in the kidney transplantation (KT) field. The complexity and increase in the amount of data, and the multitude of nephrology registries worldwide have enabled the explosive use of AI within the field. Nephrologists in many countries are already at the center of experiments and advances in this cutting-edge technology and our aim is to generalize the use of AI among nephrologists worldwide. In this paper, we provide an overview of AI from a medical perspective. We cover the core concepts of AI relevant to the practicing nephrologist in a consistent and simple way to help them get started, and we discuss the technical challenges. Finally, we focus on the KT field: the unmet needs and the potential role that AI can play to fill these gaps, then we summarize the published KT-related studies, including predictive factors used in each study, which will allow researchers to quickly focus on the most relevant issues.
- 22 December 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (4) , 1087-1100
Toward generalizing the use of artificial intelligence in nephrology and kidney transplantation
With its robust ability to integrate and learn from large sets of clinical data, artificial intelligence (AI) can now play a role in diagnosis, clinical decision making, and personalized medicine. It is probably the natural progression of traditional statistical techniques. Currently, there are many unmet needs in nephrology and, more particularly, in the kidney transplantation (KT) field. The complexity and increase in the amount of data, and the multitude of nephrology registries worldwide have enabled the explosive use of AI within the field. Nephrologists in many countries are already at the center of experiments and advances in this cutting-edge technology and our aim is to generalize the use of AI among nephrologists worldwide. In this paper, we provide an overview of AI from a medical perspective. We cover the core concepts of AI relevant to the practicing nephrologist in a consistent and simple way to help them get started, and we discuss the technical challenges. Finally, we focus on the KT field: the unmet needs and the potential role that AI can play to fill these gaps, then we summarize the published KT-related studies, including predictive factors used in each study, which will allow researchers to quickly focus on the most relevant issues.
- 6 January 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (5) , 983-991
Hospitalization patterns in HD patients in the Kingdom of Saudi Arabia: A comprehensive cohort study
Introduction: The rate of hospitalization represents a morbidity indicator in HD patients. The study aimed to evaluate hospitalization patterns in a large HD cohort.Methods: All DaVita‐KSA HD patients from October 2014 to December 2019 were included. Demographical and clinical characteristics and hospitalization data were recorded. Less than 24 h admission was excluded. Overall and cause‐specific hospitalization rates were calculated.Results: During the follow‐up period, 3982 patients with a mean age of 52.5 ± 16.8 years, 2667 hospitalizations were recorded in 34.1% of the patients and 45.6% had repeated admissions. Infectious causes accounted for 26.6% of all recorded causes vs. 15.6% for cardiovascular complications. The median hospital stay length was 11 days, while the overall annual hospitalization rate of 34.9% and the annual duration of 3.7 days per patient. Hospitalized patients had a higher risk of mortality (p < 0.001).Conclusion: Infectious complications were the leading cause of hospitalization and had the longest hospital stay.
- 6 January 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (5) , 983-991
Hospitalization patterns in HD patients in the Kingdom of Saudi Arabia: A comprehensive cohort study
Introduction: The rate of hospitalization represents a morbidity indicator in HD patients. The study aimed to evaluate hospitalization patterns in a large HD cohort.Methods: All DaVita‐KSA HD patients from October 2014 to December 2019 were included. Demographical and clinical characteristics and hospitalization data were recorded. Less than 24 h admission was excluded. Overall and cause‐specific hospitalization rates were calculated.Results: During the follow‐up period, 3982 patients with a mean age of 52.5 ± 16.8 years, 2667 hospitalizations were recorded in 34.1% of the patients and 45.6% had repeated admissions. Infectious causes accounted for 26.6% of all recorded causes vs. 15.6% for cardiovascular complications. The median hospital stay length was 11 days, while the overall annual hospitalization rate of 34.9% and the annual duration of 3.7 days per patient. Hospitalized patients had a higher risk of mortality (p < 0.001).Conclusion: Infectious complications were the leading cause of hospitalization and had the longest hospital stay.
- Open Access
- 1 June 2001
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 60 (Suppl 1) , A229
FRI0255 Polymyositis and dermatomyositis: a review of 47 cases
Background Polymyositis (PM) and Dermatomyositis (DM) are a multisystem disease characterised by acute and chronic nonsuppurative inflammation of striated muscle and skin. Objectives Objectives of this study is to describe the clinical profile, course and treatment of 47 cases of PM and DM observed over a period of 26 years. Methods Retrospective review of 47 cases with PM and DM. Results There were 36 women and 11 men with a mean age of 35 years. The classification showed: 21 cases of PM and 16 cases of DM, one case of DM was associated with a malignancy, one case of DM in children and 8 cases of an overlapping syndrome. Muscle weakness and myalgia were constant, non destructive arthritis or arthralgia were observed in 32 cases, calcinosis in 2 patients (1 DM in children and 1 overlapping syndrome with scleroderma). Results of biological tests, erythrocyte sedimentation rate and serum enzyme determination were abnormal in respectively 29 cases and 46 cases. The electromyogram was generally of a myogenic type with spontaneous activity (39/41). Steroïd therapy is prescribed in all cases and additional immunosuppressive drug (methotrexate, cyclophosphamide) is performed in 15 cases. Conclusion DM and PM are a multisystemic disease with good response to only steroïd therapy associated to immunosuppressive drugs.
- 1 June 2001
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 60 (Suppl 1) , A229
Open AccessFRI0255 Polymyositis and dermatomyositis: a review of 47 cases
Background Polymyositis (PM) and Dermatomyositis (DM) are a multisystem disease characterised by acute and chronic nonsuppurative inflammation of striated muscle and skin. Objectives Objectives of this study is to describe the clinical profile, course and treatment of 47 cases of PM and DM observed over a period of 26 years. Methods Retrospective review of 47 cases with PM and DM. Results There were 36 women and 11 men with a mean age of 35 years. The classification showed: 21 cases of PM and 16 cases of DM, one case of DM was associated with a malignancy, one case of DM in children and 8 cases of an overlapping syndrome. Muscle weakness and myalgia were constant, non destructive arthritis or arthralgia were observed in 32 cases, calcinosis in 2 patients (1 DM in children and 1 overlapping syndrome with scleroderma). Results of biological tests, erythrocyte sedimentation rate and serum enzyme determination were abnormal in respectively 29 cases and 46 cases. The electromyogram was generally of a myogenic type with spontaneous activity (39/41). Steroïd therapy is prescribed in all cases and additional immunosuppressive drug (methotrexate, cyclophosphamide) is performed in 15 cases. Conclusion DM and PM are a multisystemic disease with good response to only steroïd therapy associated to immunosuppressive drugs.